@article {Zeydan4887作者= {Burcu Zeydan和伊丽莎白·阿特金森和Carin史密斯和莉莉安娜Gazzuola罗卡沃尔特·罗卡和马克基冈和布莱恩Weinshenker Kejal Kantarci和Orhun Kantarci}, title ={未产妇与女性进行性多发性硬化的早期进化(4887)},体积={94}={15}补充数量,elocation-id ={4887} ={2020},出版商= {Wolters Kluwer健康,公司代表美国神经病学学会},文摘={摘要目的:探讨协会的怀孕状况与年龄发病进展型多发性硬化症(MS)。首页背景:女性性是最重要的风险因素然而女士怀孕状态的进化进步协会女士并没有得到充分的研究。设计/方法:累进女士临床系列(n = 202, 134名妇女、68人)进行了研究。怀孕(奇偶校验/ para:怀孕数量达到可行的孕龄)和时代进步的发病和复发缓和女士女士(名RRMS)进行评估。结果:未生育过的妇女(n = 32)早些时候曾进步女士(PMS)发病(41.4 {\ textpm} 12.6岁)比女性> = 1平价(n = 95;47.1 {\ textpm} 9.7岁)(p = 0.012)。PMS发病年龄也增加了平价量趋势(para 0: 41.4 {\ textpm} 12.6年,帕拉1 {\ textendash} 3: 46.4 {\ textpm} 9.2年,对位> = 4:52.6 {\ textpm} 12.9岁)(p = 0.002)。在二级进步女士(spm)只有子群,未生育过的女性早前spm发病年龄(n = 19;41.5 {\ textpm} 9.2岁)比女性> = 1平价(n = 57;47.3 {\ textpm} 10.6岁)(p = 0.049)。名RRMS发病年龄也早在相同的未生育过的分组(27.5 {\ textpm} 7.0岁)比女性> = 1平价(33.0 {\ textpm} 9.4岁)(p = 0.021)。剂量效应趋势再次观察到平价spm发病年龄(para 0: 41.5 {\ textpm} 9.2年,帕拉1 {\ textendash} 3: 46.2 {\ textpm} 9.9年,对位> = 4:52.6 {\ textpm} 12.9岁)(p = 0.010)和名RRMS发病年龄(para 0: 27.5 {\ textpm} 7.0年,帕拉1 {\ textendash} 3: 32.4 {\ textpm} 9.3年,对位> = 4:35.8 {\ textpm} 9.8岁)(p = 0.012)。结论:未产妇似乎与早期进化进步女士有进一步的研究需要一个更大的理解是否妊娠相关因素导致的早期发展进步的女士,还是MS-associated因素导致未产妇通过选择或由于生理原因。披露:Zeydan博士没有披露。阿特金森博士没有披露。 Dr. Smith has nothing to disclose. Dr. Gazzuola Rocca has nothing to disclose. Dr. Rocca has nothing to disclose. Dr. Keegan has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Publishing royalties from Cambridge University Press for {\textquotedblleft}Common Pitfalls in Multiple Sclerosis and CNS Demyelinating Diseases{\textquotedblright}. Dr. Keegan has received research support from Biogen. Dr. Weinshenker has received personal compensation from Alexion, Chugai/Roche, MedImmune, Mitsubishi Tanabe Pharma, Viela Bio. Dr Weinshenker has received research support from Alexion Pharmaceuticals, Terumo BCT.Dr. Kantarci has nothing to disclose. Dr. Kantarci has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novartis and Biogen. Dr. Kantarci has received research support from Biogen, the Multiple Sclerosis Society, the Mayo Foundation, and the Hilton Foundation.}, issn = {0028-3878}, URL = {//www.ez-admanager.com/content/94/15_Supplement/4887}, eprint = {//www.ez-admanager.com/content}, journal = {Neurology} }